Fibrinolytic therapy combining

Topol EJ, Reperfusion therapy for acute myocardial infarction with fibrinolytic therapy or combination reduced fibrinolytic therapy and platelet glycoprotein llb/llla inhibition the GUSTO V randomized trial. Lancet 2001 357 1 905,... 

Efficacy and safety oftenecteplase in combination with enoxaparin, abciximab, or unfractionated heparin the ASSENT-3 randomized trial in acute myocardial infarction. Lancet 2001 358 605. LincoffAM, Califf RM, Van De WerfE etal. Mortality at I year with combination platelet glycoprotein llb/llla inhibition and reduced-dose fibrinolytic therapy vs conventional fibrinolytic therapy for acute myocardial infarction GUSTO V randomized trial. JAMA 2002 288 2130. 

Ultrasound-assisted soft digestion has been used for other practical purposes from which analytical chemists can derive new applications. One case in point is in medicine, where ultrasound has been used as an adjunctive therapeutic treatment for clot dissolution of pharmacological thrombolysis. The combination of externally applied low-frequency high-intensity US with fibrinolytic therapy resulted in more rapid and complete reperfusion than the application of US or administration of fibrinolytic agents alone [42]. 

Initial fibrinolytic therapy (in patients who have no absolute contraindication to thrombolysis) should be combined with administration of conjunctive pharmacological agents to enhance lysis and minimize the risk of Weeding. 

If a fibrinolytic agent is administered, UFH is given concomitantly with alteplase, reteplase, and tenecteplase, but UFH is not administered with streptokinase because no benefit of combined therapy has been demonstrated. Rates of reinfarction are higher if UFH is not given with the fibrin-selective agents. 

Savonitto S, Armstrong PW, Lincoff AM, et al. Risk of intracranial haemorrhage with combined fibrinolytic and glycoprotein llb/llla inhibitor therapy in acute myocardial infarction. Dichotomous response as a function of age in the GUSTO V trial. Eur Heart J 2003 24 1807. 

Combination reperfusion therapy with reduced-dose fibrinolytic and a glycoprotein Ilb/IIIa inhibitor for patients with a large quantity of anterior myocardium at risk and at low risk for bleeding. 

---